Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
Terazosin Hydrochloride
Terazosin hydrochlor · Terazosin HCL dihydrate · TERAZOSIN MONOHYDROCHLORIDE DIHYDRATE · Hytrinex · iperazinehcl2h2o · Dysalfa dihydrate · Flotrin dihydrate · Heitrin dihydrate
식별자 및 물리적 특성
| CAS No. | 70024-40-7 |
|---|---|
| 분자식 | C19H30ClN5O6 |
| 평균 분자량 | 459.9 g/mol |
| 단동위원소 질량 | 459.18846136 g/mol |
| SMILES | COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC.Cl.O.O |
| InChIKey | NZMOFYDMGFQZLS-UHFFFAOYSA-N |
| PubChem CID | 63016 |
| ChEMBL | CHEMBL1201091 |
| DTXSID | DTXSID801366621 |
화학 및 물리적 성질
| 극성 표면적 | 105 |
|---|---|
| 수소 결합 공여자 수 | 4 |
| 수소 결합 수용자 수 | 10 |
| 회전 가능 결합 수 | 4 |
| 무거운 원자 수 | 31 |
| 형식 전하 | 0 |
| 복잡도 | 544 |
| Human Drugs | FDA approved drugs -> Active ingredient |
| 녹는점 | 271-274°C |
| 저장 조건 | Sealed in dry,Room Temperature |
| 용해도 | 물에 조금 녹고, 메탄올에 약간 녹고, 에탄올에 아주 조금 녹고(96%), 아세톤에는 거의 녹지 않습니다. |
| 물리적 상태 | Solid |
| 색상 | 하얀색 |
| 주요 응용 | 의약품(소분자) |
| InChI | 1S/C19H25N5O4.ClH.2H2O/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)1H2*1H2 |
| InChIKey | NZMOFYDMGFQZLS-UHFFFAOYSA-N |
| SMILES | O=C(C1CCCO1)N1CCN(C2N=C3C(C=C(C(=C3)OC)OC)=C(N)N=2)CC1.[H]Cl.[H]O[H].[H]O[H] |
화학적 성질
White or slightly yellow, crystalline powder.
안전 및 규제
| Treatment | Should overdosage of Terazosin lead to hypotension, support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by keeping the patient in the supine position. If this measure is inadequate, shock should first be treated with volume expanders. If necessary, vasopressors should then be used and renal function should be monitored and supported as needed. Laboratory data indicate that Terazosin is highly protein boundtherefore, dialysis may not be of benefit. (L1712) |
|---|---|
| 건강 영향 | Hypotension, palpitations, postural hypotension, syncope, peripheral edema, weight gain, dyspnea, nasal congestion/rhinitis, impotence. |
| 노출 경로 | Oral. Essentially completely absorbed in man (90% bioavailability). |
| 독성 요약 | Terazosin selectively and competitively inhibits vascular postsynaptic alpha(1)-adrenergic receptors, resulting in peripheral vasodilation and a reduction of vascular resistance and blood pressure. Unlike the nonselective alph-adrenergic blockers phenoxybenzamine and phentolamine, terazosin does not block presynaptic alpha(2)-receptors and, hence, does not cause reflex activation of norepinephrine release to produce reflex tachycardia. |
| Signs and Symptoms | Asthenia, postural hypotension, dizziness, somnolence, nasal congestion/rhinitis. |
| Carcinogen Classification | No indication of carcinogenicity to humans (not listed by IARC). |
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)Terazosin hydrochloridevNo-DILI-concernNo matchDOI:10.1016/j.drudis.2016.02.015 |
| Toxicity Data | LD50: 259.3mg/kg (parental-intravenous, Mouse) (A308) |
| 수질 위해 등급(WGK) | WGK 3 |
| RTECS 번호 | TK8046000 |
| 독성 | LD50 in male, female rats (mg/kg): 277, 293 i.v. (Fort) |
| 관세 코드 | 2934990002 |
| 위험 문구(R) | 22 |
| 위험 표시 | Xn |
| 위험 등급 | Eye Irrit. 2 |
| 저장 분류 | 11 - Combustible Solids |
용도
용도
Terazosin Hydrochloride Dihydrate is an α-1-adrenergic blocker related to prazosin.